Atrial natriuretic factor enhances norepinephrine uptake in circumventricular organs, locus coeruleus and nucleus tractus solitarii of the rat.

Neurosci Lett

Cátedras de Fisiología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Argentina.

Published: September 1995

The effects of atrial natriuretic factor (ANF) on norepinephrine (NE) uptake in circumventricular organs (organum vasculosum lamina terminalis, organum subfornicale and area postrema), locus coeruleus and nucleus tractus solitarii were studied in the rat. Experiments were carried out in vitro using nuclei obtained according to the punch-out technique. Results showed that 100 nM ANF enhanced NE uptake in all nuclei studied. These results suggest that ANF may be indirectly related to the control of cardiocirculatory functions, hydroelectrolyte balance, neuroendocrine secretions, nutrient and metabolic homeostasis, through the modulation of noradrenergic neurotransmission at the neuronal presynaptic level.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0304-3940(95)11891-yDOI Listing

Publication Analysis

Top Keywords

atrial natriuretic
8
natriuretic factor
8
norepinephrine uptake
8
uptake circumventricular
8
circumventricular organs
8
locus coeruleus
8
coeruleus nucleus
8
nucleus tractus
8
tractus solitarii
8
factor enhances
4

Similar Publications

Background: In heart failure (HF) patients with a higher left ventricular ejection fraction (LVEF), the B-type natriuretic peptide (BNP) level is yet to be fully assessed. Accordingly, we hypothesized that the BNP level should be higher in patients with a higher LVEF range based on the previous finding that such patients were associated with a worse prognosis.

Methods And Results: In our multicenter, prospective, observational cohort for the composite endpoint of all-cause death and readmission due to HF, including patients with LVEF >40% at hospital discharge, we obtained LVEF, E/e', and BNP levels in 231 patients.

View Article and Find Full Text PDF

Natriuretic peptides (NPs) bind to glomerular podocytes and attenuate glomerular injury. The beneficial effects of NPs are negatively regulated by the NP clearance receptor (NPRC), which is highly expressed in podocytes. To determine if inhibiting NPRC is podocyte protective, we examined the effects of deleting NPRC in both cultured podocytes and in vivo.

View Article and Find Full Text PDF

The diagnostic yield of non-invasive testing features in cardiac amyloidosis.

Nucl Med Rev Cent East Eur

March 2025

Clinical Department of Nuclear Medicine and Radiation Protection, Clinical Hospital Centre Zagreb, Zagreb, Croatia.

Background: Cardiac amyloidosis (CA) is a progressive disease in which amyloid fibrils infiltrate the heart muscle. This study aimed to identify features from cardiac biomarkers, electrocardiography (ECG), and echocardiography that may distinguish between transthyretin amyloidosis (ATTR) scintigraphy-positive and negative patients.

Material And Methods: Seventy-eight consecutive patients, median age 69 years (range 34-81), with suspected CA, negative serum free light chains, and negative serum and urine protein electrophoresis with immunofixation, referred to cardiac scintigraphy between 2021 and 2024, were retrospectively enrolled.

View Article and Find Full Text PDF

We encountered a case of a one-year-old girl who was diagnosed with focal atrial tachycardia (FAT) at two months old. The FAT was controlled with medical treatment. However, she later developed pallor and tachycardia, with a heart rate of 180 beats per minute (bpm).

View Article and Find Full Text PDF

Background: Cardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life. In this review, we evaluated the pharmacologic profile and clinical outcomes for mavacamten and aficamten, 2 cardiac myosin inhibitors investigated in symptomatic hypertrophic cardiomyopathy.

Methods And Results: Using a systematic search, 10 clinical trials with safety and efficacy data for either drug in obstructive hypertrophic cardiomyopathy (oHCM) and nonobstructive hypertrophic cardiomyopathy were included.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!